Trial Profile
A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Enoxaparin sodium; Warfarin
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AMPLIFY
- Sponsors Bristol-Myers Squibb
- 16 May 2022 Data from ARISTOTLE: NCT00412984; AVERROES: NCT00496769; AMPLIFY: NCT00643201; AMPLIFY-EXT: NCT00633893; ADVANCE-1: NCT00371683; ADVANCE-2: NCT00452530; ADVANCE-3: NCT00423319 studies has been used to assess apixaban use in obese patients published in the American Journal of Cardiovascular Drugs
- 22 Apr 2021 Results of post hoc analysis of the AMPLIFY trial published in the Advances in Therapy
- 01 Sep 2020 Results of meta analysis determining the efficacy and safety of NOACs vs. VKAs in patients with different age, sex and renal function for the treatment of VTE presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology